FATE compared with AMGN: revenue, margins and what each company keeps, and the suppliers and customers both name

FATEFate Therapeutics Inc

Mkt capRevenueRevenue

AMGNAmgen Inc

Mkt capRevenueRevenue

Compare

FATEFate Therapeutics Inc

AMGNAmgen Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

FATE

0 of 3at or beyond implied

Reportimpliedrealized× implied

Q3 FY26—▼−11.48%—

Q2 FY26±20.5%▼−7.35%×0.36

May 13 '26±57.5%▼−5.11%×0.09

Q1 FY26±21.3%▲+5.41%×0.25

AMGN

4 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±3.7%▲+3.73%×1.00

Q2 FY26±4.1%▲+4.57%×1.12

= impliedFATE realized, solidAMGN realized, hatchedOne scale, both sides: full bar = 58%× = |realized| ÷ impliedSource: market data

Q1 FY26

±3.9%

▼−4.75%

×1.23

Feb 4 '26±3.7%▲+8.15%×2.22

FATEFate Therapeutics Inc

1.86· pre 1.81· delayed

Mkt cap$224.9MRevenue$2MQ2 FY26Revenue$7MFY25

AMGNAmgen Inc

461.49· pre 448.53· delayed

Pre-marketNov 6 '26delayed

Mkt cap$249.0BRevenue$10.4BQ3 FY26Revenue$36.8BFY25

Compare

Pre-marketNov 6 '26delayed

FATEFate Therapeutics Inc

AMGNAmgen Inc

1.86pre 1.81delayed

Price

461.49pre 448.53delayed

$224.9M

Mkt cap

$249.0B

Q2 FY26$2M

Revenue

$10.4BQ3 FY26

FY25$7M

Revenue

$36.8BFY25

FATE1.86vsAMGN461.49Pre-marketNov 6 '26delayed